Good morning :)
$
₹
Krystal Biotech Inc

Krystal Biotech Inc

KRYS

NASDAQ
Asset Logo

Krystal Biotech Inc

KRYS

NASDAQ
$320.070.65% (-2.1)
$
₹
$320.070.65% (-2.1)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $9.6B the stock is ranked 1002

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

40.77
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.44
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$7.98
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

54.82%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
11 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+22.74%

Earnings Growth

+11.27%

Rev. Growth

+28.02%

See Detailed Forecast

Company Profile

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
81.66
81.66
1Y Return
24.93%
24.93%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.26
27.26
1Y Return
46.59%
46.59%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
23.76%
23.76%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.80
29.80
1Y Return
23.04%
23.04%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
794.17%
794.17%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 22.74% growth, versus a trailing 3-year CAGR of 42.07%.

2026
Current$322.17Baseline
Analyst Target - 1 year
Target$395.44+22.74%

All values in $

202220232024202520262027$162.22$253.14$344.06Target+22.74%
2026
Current$322.17Baseline
Analyst Target - 1 year
Target$395.44+22.74%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$389.13Baseline
Forecast for Dec 2026
High$516.4+32.71%
Average$498.16+28.02%
Low$484.24+24.44%

All values in $ Million

2021202220232024202520260050.69290.51389.13Low+24.44%Average+28.02%High+32.71%
2025
Current$389.13Baseline
Forecast for Dec 2026
High$516.4+32.71%
Average$498.16+28.02%
Low$484.24+24.44%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$6.85Baseline
Forecast for Dec 2026
High$10.26+49.84%
Average$7.62+11.27%
Low$6.77-1.17%

All values in $

202120222023202420252026-3.13-4.51-2.723.46.85Low-1.17%Average+11.27%High+49.84%
2025
Current$6.85Baseline
Forecast for Dec 2026
High$10.26+49.84%
Average$7.62+11.27%
Low$6.77-1.17%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

97.8
79.3
107.1
51.4
116.3
55.9
119.2
54.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue45.2570.2883.8491.1388.1896.0497.8107.10116.35119.22
Net Income0.9315.5627.1845.4735.7338.3379.3651.455.9354.76
Net Profit Margin2.05%22.15%32.41%49.90%40.52%39.91%81.15%47.99%48.06%45.93%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Krystal Biotech Inc 40.777.44-
AbbVie Inc81.6650.450.54
Amgen Inc27.2618.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare KRYS with any stock or ETF
Compare KRYS with any stock or ETF
Comparing from
KRYS
ABBV
AMGN
Loading...

Frequently asked questions

  1. Krystal Biotech Inc (KRYS) share price today is $320.07 as of October 23, 2026 at 1:30 AM IST. The stock touched a day high of $328.19 and a day low of $317.69.

  2. Krystal Biotech Inc stock trades on NASDAQ under the ticker symbol KRYS.

  3. Krystal Biotech Inc's market capitalization is $9.63B as of October 23, 2026 at 1:30 AM IST.

  4. Krystal Biotech Inc's price-to-earnings (P/E) ratio is 40.77 as of October 22, 2026.

  5. Krystal Biotech Inc's price-to-book (P/B) ratio is 7.44 as of October 22, 2026.

  6. Yes, You can buy Krystal Biotech Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Krystal Biotech Inc shares in three steps: 1. Search Krystal Biotech Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Krystal Biotech Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Krystal Biotech Inc (KRYS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0312 shares at the current price of $320.07.

Loading...